The contribution of the ABCG2 C421A polymorphism to cancer susceptibility: a meta-analysis of the current literature

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Chen, Pin ^a   Zhao, Lin ^a   Zou, Peng ^a   Xu, Haitao ^a   Lu, Ailin ^a   Zhao, Peng ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN;

ARTICLE; ATP BINDING CASSETTE G2 GENE; CANCER CLASSIFICATION; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; MAJOR CLINICAL STUDY; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC ERROR; TUMOR GENE;

ALLELES; ATP-BINDING CASSETTE TRANSPORTERS; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS;

EID: 84865574322     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-383     Document Type: Article

References (41)

1. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004, 4(11):850-860. 10.1038/nrc1476, 15516958.
2. Bartsch H, Dally H, Popanda O, Risch A, Schmezer P. Genetic risk profiles for cancer susceptibility and therapy response. Recent Results Cancer Res 2007, 174:19-36. 10.1007/978-3-540-37696-5_2, 17302182.
3. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003, 3(3):155-168. 10.1038/nrc1011, 12612651.
4. Dean M, Allikmets R. Complete characterization of the human ABC gene family. J Bioenerg Biomembr 2001, 33(6):475-479. 10.1023/A:1012823120935, 11804189.
5. Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 2001, 1520(3):234-241. 10.1016/S0167-4781(01)00270-6, 11566359.
6. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998, 95(26):15665-15670. 10.1073/pnas.95.26.15665, 28101, 9861027.
7. Lechner A, Leech CA, Abraham EJ, Nolan AL, Habener JF. Nestin-positive progenitor cells derived from adult human pancreatic islets of Langerhans contain side population (SP) cells defined by expression of the ABCG2 (BCRP1) ATP-binding cassette transporter. Biochem Biophys Res Commun 2002, 293(2):670-674. 10.1016/S0006-291X(02)00275-9, 12054520.
8. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001, 61(8):3458-3464.
9. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001, 7(9):1028-1034. 10.1038/nm0901-1028, 11533706.
10. Krishnamurthy P, Schuetz JD. Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 2006, 46:381-410. 10.1146/annurev.pharmtox.46.120604.141238, 16402910.
11. Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RC, de Jong LA, Pluim D, Beijnen JH, Schellens JH. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001, 7(4):935-941.
12. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 2005, 7(1):E118-133. 10.1208/aapsj070112, 2751502, 16146333.
13. Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A. ABCG2 - a transporter for all seasons. FEBS Lett 2004, 567(1):116-120. 10.1016/j.febslet.2004.03.123, 15165903.
14. Agundez JA. Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab 2008, 9(6):520-531. 10.2174/138920008784892083, 18680472.
15. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999, 39:361-398. 10.1146/annurev.pharmtox.39.1.361, 10331089.
16. Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001, 167(1):3-23. 10.1016/S0300-483X(01)00454-1, 11557126.
17. Singh MS, Michael M. Role of xenobiotic metabolic enzymes in cancer epidemiology. Methods Mol Biol 2009, 472:243-264. 10.1007/978-1-60327-492-0_10, 19107436.
18. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997, 27(2-3):161-170.
19. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999, 22(3):231-238. 10.1038/10290, 10391209.
20. Gunderson KL, Kuhn KM, Steemers FJ, Ng P, Murray SS, Shen R. Whole-genome genotyping of haplotype tag single nucleotide polymorphisms. Pharmacogenomics 2006, 7(4):641-648. 10.2217/14622416.7.4.641, 16768648.
21. Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, Terakawa N, et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 2005, 33(1):94-101.
22. McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006, 25(11):1639-1648. 10.1038/sj.onc.1209373, 16550164.
23. Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura K, Ueno K, Kamakura S, Kitakaze M, Shirao K, et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003, 13(12):741-757. 10.1097/00008571-200312000-00005, 14646693.
24. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002, 1(8):611-616.
25. Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 2008, 23(4):223-235. 10.2133/dmpk.23.223, 18762709.
26. Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 2004, 109(2):238-246. 10.1002/ijc.11669, 14750175.
27. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22(4):719-748.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188. 10.1016/0197-2456(86)90046-2, 3802833.
29. Andersen V, Ostergaard M, Christensen J, Overvad K, Tjonneland A, Vogel U. Polymorphisms in the xenobiotic transporter multidrug resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a danish prospective case-cohort study. BMC Cancer 2009, 9:407. 10.1186/1471-2407-9-407, 2797527, 19930591.
30. Campa D, Butterbach K, Slager SL, Skibola CF, de Sanjose S, Benavente Y, Becker N, Foretova L, Maynadie M, Cocco P, et al. A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk. Int J Cancer 2011, 131(4):803-812.
31. Campa D, Pardini B, Naccarati A, Vodickova L, Novotny J, Forsti A, Hemminki K, Barale R, Vodicka P, Canzian F. A gene-wide investigation on polymorphisms in the ABCG2/BRCP transporter and susceptibility to colorectal cancer. Mutat Res 2008, 645(1-2):56-60.
32. Gardner ER, Ahlers CM, Shukla S, Sissung TM, Ockers SB, Price DK, Hamada A, Robey RW, Steinberg SM, Ambudkar SV, et al. Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU Int 2008, 102(11):1694-1699. 10.1111/j.1464-410X.2008.07913.x, 2605573, 18710444.
33. Hu LL, Wang XX, Chen X, Chang J, Li C, Zhang Y, Yang J, Jiang W, Zhuang SM. BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma. Carcinogenesis 2007, 28(8):1740-1744. 10.1093/carcin/bgm113, 17494054.
34. Korenaga Y, Naito K, Okayama N, Hirata H, Suehiro Y, Hamanaka Y, Matsuyama H, Hinoda Y. Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma. Int J Cancer 2005, 117(3):431-434. 10.1002/ijc.21187, 15906349.
35. Muller P, Asher N, Heled M, Cohen SB, Risch A, Rund D. Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups. Leuk Res 2008, 32(6):919-929. 10.1016/j.leukres.2007.10.011, 18207572.
36. Semsei AF, Erdelyi DJ, Ungvari I, Kamory E, Csokay B, Andrikovics H, Tordai A, Csagoly E, Falus A, Kovacs GT, et al. Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia. Leuk Res 2008, 32(8):1214-1220. 10.1016/j.leukres.2007.12.009, 18243305.
37. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002, 2(5):331-341. 10.1038/nrc795, 12044009.
38. Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins introduction. Pflugers Arch 2004, 447(5):465-468. 10.1007/s00424-003-1192-y, 14624363.
39. Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 2005, 6(2):109-118. 10.1038/nrg1522, 15716907.
40. Conde L, Halperin E, Akers NK, Brown KM, Smedby KE, Rothman N, Nieters A, Slager SL, Brooks-Wilson A, Agana L, et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet 2010, 42(8):661-664. 10.1038/ng.626, 2913472, 20639881.
41. Slager SL, Rabe KG, Achenbach SJ, Vachon CM, Goldin LR, Strom SS, Lanasa MC, Spector LG, Rassenti LZ, Leis JF, et al. Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood 2011, 117(6):1911-1916. 10.1182/blood-2010-09-308205, 3056639, 21131588.